24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Actavis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:48
Israel’s gaming industry employs 14,000 workers and makes up 2% of the GDP
15:44
Innoviz secures $80M in development funding as cash reserves run thin
15:22
"Israeli companies are responsible for 5% of global mobile game downloads"
15:18
"Google's AI models allow users to generate content and integrate it into games in real-time"
More stories
Buzz
Most popular
Daily
Weekly
1
Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?
2
Israeli fintech Morning acquired for $150 million by Italy's TeamSystem
3
$41B in exits: Why Israeli cyber startups are a global powerhouse
4
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
5
Amazon-backed robotics startup BionicHIVE shuts down with $18M debt
More news
Actavis
5 stories about Actavis
Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19
|
Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17
|
Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17
|
Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended
Please ensure Javascript is enabled for purposes of
website accessibility